Foundation Medicine, Inc. services

Discover tissue AND blood-based FDA-approved comprehensive genomic profiling testing for all solid tumors with FoundationOne®CDx and FoundationOne®Liquid CDx. In addition, FoundationOne®Heme is a laboratory developed test for hematologic malignancies, sarcomas, or solid tumors where fusion detection is desired. 

Our Decision Support services are designed to present patient results in the clearest way possible and to provide the information you need to take action in establishing treatment plans. Ranging from interpretation of results on each report to expert consultations and ongoing education, these services can help you make the most of comprehensive genomic profiling (CGP) in your practice.

Discuss patient results with our team of oncologists and pathologists. This robust on-call program is covered by physicians and Medical Science Liaisons (MSLs) within Foundation Medicine or by external oncologists who are subject matter experts and consultants for Foundation Medicine.

Simplified test results provide information about genomic findings and biomarkers and their associated targeted therapies when available. We also provide information on clinically relevant alterations and available clinical trial options specific to each patient’s cancer.

Our genomic information knowledgebase is continuously evolving, informed by every clinical sample sequenced with Foundation Medicine’s comprehensive genomic profiling tests. You can also access a unique clinicogenomic data set through our partnership with Flatiron Health, a leading provider of clinical data.

Foundation Medicine matches patients to precision oncology trials based on genomic alterations, tumor type, and age. Our team of expert curators and genomicists helps facilitate awareness of genomically matched clinical trial options for your patients.